These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11142331)

  • 1. Applying Nuclear Regulatory Commission guidelines to the release of patients treated with sodium iodine-131.
    Tuttle WK; Brown PH
    J Nucl Med Technol; 2000 Dec; 28(4):275-9. PubMed ID: 11142331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reflections on cancer treatment and the federal agency regulations.
    Saenger EL; Kereiakes JG
    Radiology; 1980 Dec; 137(3):865-6. PubMed ID: 7444073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient release issue reopened.
    J Nucl Med; 2010 Dec; 51(12):13N. PubMed ID: 21098785
    [No Abstract]   [Full Text] [Related]  

  • 4. New NRC patient release guidelines: major quality of life & cost-containment benefits.
    Grigsby PW; Baker SM; Siegel BA; Eichling JO
    Adm Radiol J; 1998 Apr; 17(4):18-21. PubMed ID: 10181525
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
    Coover LR; Silberstein EB; Kuhn PJ; Graves MW
    J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After
    Wu D; Gomes Lima CJ; Bloom G; Burman KD; Wartofsky L; Van Nostrand D
    J Nucl Med; 2020 Mar; 61(3):397-404. PubMed ID: 31451488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.
    ; Sisson JC; Freitas J; McDougall IR; Dauer LT; Hurley JR; Brierley JD; Edinboro CH; Rosenthal D; Thomas MJ; Wexler JA; Asamoah E; Avram AM; Milas M; Greenlee C
    Thyroid; 2011 Apr; 21(4):335-46. PubMed ID: 21417738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Professional groups respond.
    J Nucl Med; 2010 Dec; 51(12):13N. PubMed ID: 21098784
    [No Abstract]   [Full Text] [Related]  

  • 9. Online regulatory guide errors.
    Dawry FP
    J Nucl Med; 2002 Feb; 43(2):284. PubMed ID: 11858234
    [No Abstract]   [Full Text] [Related]  

  • 10. Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice.
    Biermann M; Pixberg MK; Dörr U; Dietlein M; Schlemmer H; Grimm J; Zajic T; Nestle U; Ladner S; Sepehr-Rezai S; Rosenbaum S; Puskás C; Fostitsch P; Heinecke A; Schuck A; Willich N; Schmid KW; Dralle H; Schober O;
    Nuklearmedizin; 2005; 44(6):229-34, 236-7. PubMed ID: 16400382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Surgery and follow-up 131I therapy in patients with differentiated thyroid carcinoma in the south-east of the Netherlands, 1983-1996, compliance with the 1987 consensus guidelines: additional data].
    Kuijpens JL; Verheij CD; Haak HR; Ribot JG; Hoekstra OS; Coebergh JW
    Ned Tijdschr Geneeskd; 2004 Sep; 148(37):1835-6. PubMed ID: 15495514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dose rates post 131I therapy and advice to patients on discharge from hospital.
    Kettle AG; Barrington SF; O'Doherty MJ
    Health Phys; 1997 Oct; 73(4):711. PubMed ID: 9314238
    [No Abstract]   [Full Text] [Related]  

  • 13. Licensee over-reliance on conservatisms in NRC guidance regarding the release of patients treated with 131I.
    Siegel JA; Marcus CS; Stabin MG
    Health Phys; 2007 Dec; 93(6):667-77. PubMed ID: 17993847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy.
    Parthasarathy KL; Crawford ES
    J Nucl Med Technol; 2002 Dec; 30(4):165-71; quiz 172-3. PubMed ID: 12446749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure.
    Gabriel S; Farman-Ara B; Bourrelly M; Carpentier O; Sebag F; Palazzo FF; De Micco C; Mancini J; Henry JF; Mundler O; Taïeb D
    Nucl Med Commun; 2011 Sep; 32(9):829-33. PubMed ID: 21633315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NRC absorbed dose reconstruction for family member of 131I therapy patient: case study and commentary.
    Marcus CS; Siegel JA
    J Nucl Med; 2004 Apr; 45(4):13N-6N, 37N. PubMed ID: 15073236
    [No Abstract]   [Full Text] [Related]  

  • 17. Radiation safety considerations for post-iodine-131 thyroid cancer therapy.
    Culver CM; Dworkin HJ
    J Nucl Med; 1992 Jul; 33(7):1402-5. PubMed ID: 1613585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital discharge of patients with thyroid carcinoma treated with 131I.
    Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
    J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient therapeutic 131I for thyroid cancer.
    Panzegrau B; Gordon L; Goudy GH
    J Nucl Med Technol; 2005 Mar; 33(1):28-30. PubMed ID: 15731017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid reports: insight into radioiodine ablation and new guidelines for nodule management.
    J Nucl Med; 2006 Mar; 47(3):15N, 26N. PubMed ID: 16594104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.